Glucocorticoid monotherapy vs. immunosuppressant-combined therapy in retroperitoneal fibrosis: clinical evidence and mechanistic insights from bioinformatics

Clinical evidence from literature and mechanistic insights from bioinformatics both suggest a potential benefit of combination therapy in RPF. However, the evidence remains associative and exploratory. Further randomized controlled trials are warranted to evaluate the potential benefits and risks associated with the addition of immunosuppressants in patients with RPF.